Abstract
A mouse model of the neurodegenerative disease spinocerebellar ataxia type 1 reveals that changes in gene expression begin many weeks before the onset of symptoms.
References
Lin X., Antalffy, B., Kang, D., Orr, H. T. & Zoghbi, H. Y. Nat. Neurosci. 3, 157– 163 (2000).
Lunkes, A., Trottier, Y. & Mandel, J. L. Essays Biochem. 33, 149– 163 (1999).
Orr, H. T. et al. Nat. Genet. 4, 221–226 (1993).
Klement, I. A. et al. Cell 95, 41–53 (1998).
Schwarcz, R., Foster, A. C., French, E. D., Whetsell, W. O. Jr. & Kohler, C. Life Sci. 35, 19–32 (1984).
Greenamyre, J. T. Arch. Neurol. 43, 1058–1063 (1986).
diFiglia, M. Trends Neurosci. 13, 286–289 (1990).
Beal, M. F. Ann. Neurol. 38, 357–366 (1995).
Doble, A. Pharmacol. Ther. 81, 163–221 (1999).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nussbaum, R., Auburger, G. Neurodegeneration in the polyglutamine diseases: Act 1, Scene 1. Nat Neurosci 3, 103–104 (2000). https://doi.org/10.1038/72042
Issue Date:
DOI: https://doi.org/10.1038/72042
- Springer Nature America, Inc.
This article is cited by
-
Experimental therapeutics in transgenic mouse models of Huntington's disease
Nature Reviews Neuroscience (2004)